{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:20:55Z","timestamp":1788380455146,"version":"build-2803163510"},"reference-count":131,"publisher":"Informa UK Limited","issue":"7-8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/13543784.2025.2532443","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T16:13:54Z","timestamp":1752077634000},"page":"639-653","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Antibiotics and non-traditional antimicrobial agents for\n            <i>Pseudomonas aeruginosa<\/i>\n            in clinical phases 1, 2, and 3 trials"],"prefix":"10.1080","volume":"34","author":[{"given":"Laura T.","family":"Romanos","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS)","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS)","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chara","family":"Tsiampali","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva D.","family":"Tzvetanova","sequence":"additional","affiliation":[{"name":"European University Cyprus School of Medicine","place":["Nicosia, Cyprus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS)","place":["Athens, Greece"]},{"name":"European University Cyprus School of Medicine","place":["Nicosia, Cyprus"]},{"name":"Tufts University School of Medicine","place":["Boston, Massachusetts, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00031-19"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0506-2017"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.05.016"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1816-5"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178178"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-014-0635-z"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-018-0629-6"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.12.006"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026470"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.909731"},{"key":"e_1_3_5_13_1","volume-title":"2023 antibacterial agents in clinical and preclinical development: an overview and analysis","author":"Gigante V","year":"2024","unstructured":"Gigante V , Alm R , Cameron A, et al. 2023 antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2024."},{"key":"e_1_3_5_14_1","unstructured":"PubChem funobactam. [cited 2025 May 16]. available online https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/155337781"},{"key":"e_1_3_5_15_1","unstructured":"PubChem taniborbactam. [cited 2025 May 16]. available online https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/76902493"},{"key":"e_1_3_5_16_1","unstructured":"PubChem xeruborbactam. [cited 2025 May 16]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/140830474"},{"key":"e_1_3_5_17_1","unstructured":"PubChem apramycin. [cited 2025 May 16]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3081545"},{"key":"e_1_3_5_18_1","unstructured":"PubChem upleganan. [cited 2025 May 16]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/139600308"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13040354"},{"key":"e_1_3_5_20_1","unstructured":"PubChem Spr741. [cited 2025 May 16]. available online https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/53323381"},{"key":"e_1_3_5_21_1","unstructured":"PubChem levofloxacin. [cited 2025 May 16]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/149096"},{"key":"e_1_3_5_22_1","unstructured":"PubChem murepavadin. [cited 2025 May 16]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/91824766"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad242"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/18.supplement_e.79"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14020168"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136814"},{"key":"e_1_3_5_27_1","unstructured":"Evopoint Biosciences Inc. A multicenter randomized double-blind comparative phase 3 study to evaluate the efficacy and safety of intravenous imipenem\/cilastatin\/XNW4107 in comparison with imipenem\/cilastatin\/relebactam in adults with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia (EudraCT No. 2022-000081-18) (EUCTR No. 2022-501952-27\u201300) (IND No. 146614); clinicaltrials.gov 2025;"},{"key":"e_1_3_5_28_1","unstructured":"Evopoint Biosciences Inc. A multicenter randomized double-blind double-dummy comparative phase 3 study to evaluate the efficacy and safety of intravenous imipenem\/cilastatin\/XNW4107 in comparison with meropenem in hospitalized adults with complicated urinary tract infections including acute pyelonephritis. (EudraCT No. 2022-000061-40). clinicaltrials.gov; 2023."},{"key":"e_1_3_5_29_1","unstructured":"Evopoint Biosciences Inc. A phase 1 randomized double blind placebo controlled sequential group study to evaluate the safety tolerability and pharmacokinetics of single and multiple ascending doses of xnw4107 for injection and multiple doses of XNW4107 for injection in combination with imipenem\/cilastatin for injection in healthy adult male subjects. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_30_1","unstructured":"Evopoint Biosciences Inc. A phase 1 open-label study to evaluate the safety and intrapulmonary pharmacokinetics of XNW4107 imipenem and cilastatin in healthy subjects. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_31_1","unstructured":"Evopoint Biosciences Inc. A phase 1 single-dose randomized double blind placebo-controlled study to evaluate pharmacokinetics safety and tolerability of XNW4107 for injection in healthy adult young females and in healthy adult elderly males and females; clinicaltrials.gov 2023."},{"key":"e_1_3_5_32_1","unstructured":"Evopoint Biosciences Inc. A Phase 1 open-label study to evaluate the pharmacokinetics and safety of XNW4107 imipenem and cilastatin administered concurrently as intravenous infusion to subjects with various degrees of renal function. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00918-21"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01281-22"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304748"},{"key":"e_1_3_5_36_1","unstructured":"Venatorx Pharmaceuticals Inc. A Phase 3 randomized double-blind active controlled noninferiority study evaluating the efficacy safety and tolerability of cefepime\/VNRX-5133 in adults with complicated urinary tract infections (cUTI) including acute pyelonephritis; clinicaltrials.gov 2024"},{"key":"e_1_3_5_37_1","unstructured":"Venatorx Pharmaceuticals Inc. A Phase 3 study to evaluate cefepime-taniborbactam compared to meropenem in adults with ventilator-associated bacterial pneumonia (VABP) or ventilated hospital-acquired bacterial pneumonia (vHABP). clinicaltrials.gov; 2025."},{"key":"e_1_3_5_38_1","unstructured":"Venatorx Pharmaceuticals Inc. An open-label trial to assess the safety and pharmacokinetics of VNRX-5133 in the epithelial lining fluid of healthy adult subjects. clinicaltrials.gov; 2019."},{"key":"e_1_3_5_39_1","unstructured":"Venatorx Pharmaceuticals Inc. A Phase 1 study to evaluate the safety and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy subjects. clinicaltrials.gov; 2021."},{"key":"e_1_3_5_40_1","unstructured":"Venatorx Pharmaceuticals Inc. A Phase 1 open-label single-dose study to evaluate the pharmacokinetics safety and tolerability of VNRX-5133 with VNRX-5022 in subjects with varying degrees of renal impairment. clinicaltrials.gov; 2019."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-023-00629-8"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.294"},{"key":"e_1_3_5_43_1","unstructured":"Qpex Biopharma Inc. A Phase 1 randomized double-blind single-dose drug-drug interaction study to determine the impact of co-administration of QPX7728 on the pharmacokinetics of qpx2014 in healthy adult subjects. clinicaltrials.gov; 2022."},{"key":"e_1_3_5_44_1","unstructured":"Qpex Biopharma Inc. A Phase 1 randomized double-blind placebo-controlled ascending single and multiple-dose study of the safety tolerability and pharmacokinetics of intravenous (IV) QPX7728 alone and in combination with QPX2014 in healthy adult subjects. clinicaltrials.gov; 2022."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02705-20"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac225"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2006.11.006"},{"key":"e_1_3_5_48_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) A Phase I open-label study to assess lung pharmacokinetics and safety of a single dose of apramycin administered intravenously in healthy adult subjects. clinicaltrials.gov; 2025."},{"key":"e_1_3_5_49_1","unstructured":"Juvabis AG. A Phase I randomized double-blind placebo-controlled single ascending dose study to assess the safety tolerability and pharmacokinetics of apramycin administered intravenously in healthy adults. clinicaltrials.gov; 2021."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00505-23"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01940-24"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa217"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00426-23"},{"key":"e_1_3_5_54_1","unstructured":"Spero Therapeutics. A Phase 1 single-center open-label study to assess the intrapulmonary pharmacokinetics of SPR206 by comparing the plasma epithelial lining fluid and alveolar macrophage concentrations following the intravenous administration of SPR206 in healthy volunteers. clinicaltrials.gov; 2021."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00426-23"},{"key":"e_1_3_5_56_1","unstructured":"Spero Therapeutics. A Phase 1 two-part double-blind placebo-controlled study of the safety tolerability and pharmacokinetics of single and multiple ascending doses of spr206 in healthy volunteers. clinicaltrials.gov; 2020."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00739-21"},{"key":"e_1_3_5_58_1","unstructured":"Spero Therapeutics. A Phase 1 open-label study to assess the safety and pharmacokinetics of SPR206 following a single IV dose of SPR206 in subjects with varying degrees of renal function. clinicaltrials.gov; 2024."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00139-22"},{"key":"e_1_3_5_60_1","unstructured":"In vitro potency and spectrum of the novel polymyxin MRX-8 tested against clinical isolates of Gram-negative bacteria - PMC 2022. [cited 2025 Jun 30]. Available online https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9112888\/"},{"key":"e_1_3_5_61_1","unstructured":"MicuRx An adaptive randomized double blind placebo-controlled three-part study of the safety tolerability and pharmacokinetics of MRX-8 administered intravenously to healthy volunteers in single ascending and multiple ascending dose cohorts. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00892-19"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01239-17"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.858606"},{"key":"e_1_3_5_65_1","unstructured":"Spero Therapeutics A two-part double-blind placebo-controlled Phase I study of the safety tolerability and pharmacokinetics of single and multiple ascending doses of SPR741 in healthy volunteers. clinicaltrials.gov; 2017."},{"key":"e_1_3_5_66_1","unstructured":"Spero Therapeutics A single-center multi-arm open-label randomized 3-period crossover Phase 1 study to evaluate the DDI PK safety and tolerability of single doses of SPR741 co-administered with three different antibiotics in healthy volunteers; clinicaltrials.gov. 2018."},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753465813508445"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01744-10"},{"key":"e_1_3_5_69_1","unstructured":"Amgen A Phase 3 multi-center multinational randomized double-blind placebo-controlled study to evaluate the efficacy and safety of MP-376 (levofloxacin inhalation solution; aeroquintm) in stable cystic fibrosis patients; clinicaltrials.gov. 2024;"},{"key":"e_1_3_5_70_1","unstructured":"Amgen Phase 3 open-label randomized trial to evaluate the safety and efficacy of MP-376 inhalation solution (aeroquin) vs. tobramycin inhalation solution (tis) in stable CF patients; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_71_1","unstructured":"Amgen Phase II multi-center randomized double-blind placebo-controlled study to evaluate the safety tolerability and efficacy of three dosage regimens of MP-376 solution for inhalation given for 28 days to stable CF patients; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201008-1293OC"},{"key":"e_1_3_5_73_1","unstructured":"Amgen Phase 2 randomized double-blind placebo-controlled study to evaluate the safety tolerability and efficacy of MP-376 inhalation solution administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_74_1","unstructured":"Amgen Phase 1b randomized single-blind placebo-controlled study to evaluate the safety tolerability and pharmacokinetics of MP-376 inhalation solution administered for 5 days to chronic bronchitis patients; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_75_1","unstructured":"Amgen Phase I single and multi-dose placebo-controlled randomized dose-escalation study to evaluate the safety tolerability and PK profile of MP-376 using the PARI eFlow nebulizer for 14 days to CF patients; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_76_1","unstructured":"Amgen A Phase 1B multi-center open-label study to evaluate the safety tolerability and pharmacokinetics of MP-376 inhalation solution given daily for 14 days to stable pediatric cystic fibrosis patients.; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114066"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00490-18"},{"key":"e_1_3_5_79_1","unstructured":"Polyphor Ltd. A multicenter open label sponsor blinded randomized active controlled parallel group pivotal study to evaluate the efficacy safety and tolerability of murepavadin given with ertapenem versus an anti-pseudomonal-\u03b2-lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa. clinicaltrials.gov; 2019."},{"key":"e_1_3_5_80_1","unstructured":"Polyphor Ltd. A multicenter open-label randomized active-controlled parallel group pivotal study to investigate the efficacy safety and tolerability and pharmacokinetics of murepavadin combined with one anti-pseudomonal antibiotic versus two anti-pseudomonal antibiotics in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa. clinicaltrials.gov; 2019."},{"key":"e_1_3_5_81_1","unstructured":"Polyphor Ltd. A Phase II open-label multi-center study to assess pharmacokinetics (PK) safety and efficacy of POL7080 co-administered with standard of care (SOC) treatment in patients with ventilator-associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection. clinicaltrials.gov; 2017."},{"key":"e_1_3_5_82_1","unstructured":"Polyphor Ltd. A Phase II open-label multicenter study to assess the tolerance safety efficacy and pharmacokinetics\/pharmacodynamics (PK\/PD) of POL7080 in the treatment of patients with acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection requiring intravenous treatment. clinicaltrials.gov; 2017."},{"key":"e_1_3_5_83_1","unstructured":"Polyphor Ltd. An open-label non-randomized monocenter single-dose Phase I study to evaluate pharmacokinetics and safety of POL7080 administered as single intravenous infusion to subjects with renal impairment. clinicaltrials.gov; 2016."},{"key":"e_1_3_5_84_1","unstructured":"Polyphor Ltd. A single-center open-label two-sequence crossover study to investigate the interaction between amikacin and POL7080 in healthy subjects. clinicaltrials.gov; 2017."},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02137-x"},{"key":"e_1_3_5_86_1","unstructured":"Gamaleya Research Institute of Epidemiology and Microbiology Health Ministry of the Russian Federation An open clinical trial of the safety and efficacy of the drug fluorothiazinone 300 mg tablets (gamaleya research institute of epidemiology and microbiology health ministry of the russian federation) with the participation of adult patients with chronic bacterial cystitis. clinicaltrials.gov; 2025;"},{"key":"e_1_3_5_87_1","unstructured":"Gamaleya Research Institute of Epidemiology and Microbiology Health Ministry of the Russian Federation Randomized blind placebo-controlled study to evaluate safety and efficacy of ftortiazinon in combination with maxipime\u00ae in comparison with placebo in combination with maxipime\u00ae in the treatment of patients with complicated urinary tract infections caused by P. aeruginosa. Russian Federation: clinicaltrials.gov; 2021."},{"key":"e_1_3_5_88_1","unstructured":"Gamaleya Research Institute of Epidemiology and Microbiology Health Ministry of the Russian Federation A randomized double-blind placebo controlled clinical trial to study the efficacy and safety of the drug fluorothiazinone (gamaleya research institute of epidemiology and microbiology health ministry of the russian federation) in prophylaxis of nosocomial bacterial infections with participation of patients on mechanical ventilation. Russian Federation: clinicaltrials.gov; 2023."},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-022-00504-y"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00694-24"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00655-24"},{"key":"e_1_3_5_92_1","unstructured":"Monoclonal antibody disrupts biofilm structure and restores antibiotic susceptibility in an orthopedic implant infection model - PMC. [cited 2025 Jun 30]. Available online https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10604051\/"},{"key":"e_1_3_5_93_1","unstructured":"Trellis Bioscience LLC Phase 2 study to evaluate the efficacy and safety of TRL1068 for the treatment of chronic prosthetic joint infection of the knee or hip without exchange arthroplasty. USA: clinicaltrials.gov; 2025."},{"key":"e_1_3_5_94_1","unstructured":"Trellis Bioscience LLC Phase 1 study to evaluate the safety pharmacokinetics and pharmacodynamics of trl1068 in subjects with acute exacerbation of chronic rhinosinusitis. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11010104"},{"key":"e_1_3_5_96_1","unstructured":"Clarametyx Biosciences Inc. A Phase 1b\/2a study to evaluate the safety of CMTX-101 in combination with inhaled antibiotics in people with cystic fibrosis chronically infected with Pseudomonas aeruginosa. clinicaltrials.gov; 2025."},{"key":"e_1_3_5_97_1","unstructured":"Pseudomonas Aeruginosa Phage Product Candidates Available online 2025. [cited 2025 Apr 15]. Available from: https:\/\/www.armatapharma.com\/pipeline\/ap-pa02\/"},{"key":"e_1_3_5_98_1","unstructured":"Armata Pharmaceuticals Inc. A Phase 2 multi-center double-blind randomized placebo-controlled study to evaluate the safety phage kinetics and efficacy of inhaled AP-PA02 multi-phage therapeutic in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection. clinicaltrials.gov; 2024."},{"key":"e_1_3_5_99_1","unstructured":"Armata Pharmaceuticals Inc. A Phase 1b\/2a multi-center double-blind randomized placebo-controlled single and multiple ascending dose study to evaluate the safety and tolerability of AP-PA02 multi-phage therapeutic candidate for inhalation in subjects with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa (PA) infection; clinicaltrials.gov. 2024."},{"key":"e_1_3_5_100_1","unstructured":"Koff J. Cystic fibrosis bacteriophage study at Yale (CYPHY): a single-site randomized double-blind placebo-controlled study of bacteriophage therapy YPT-01 for Pseudomonas aeruginosa infections in adults with cystic fibrosis. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_101_1","unstructured":"BiomX Inc. A Phase 1b\/2a randomized double-blind placebo-controlled multicenter study to evaluate nebulized bacteriophage treatment in outpatient adult cystic fibrosis (CF) subjects with chronic Pseudomonas aeruginosa (PSA) pulmonary infection. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-07047-5"},{"key":"e_1_3_5_103_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A Phase 1b\/2 multi-centered randomized double-blind placebo-controlled trial of the safety and microbiological activity of a single dose of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa. clinicaltrials.gov; 2025."},{"key":"e_1_3_5_104_1","unstructured":"Aridis Pharmaceuticals. AR-501 (PanaecinTM)."},{"key":"e_1_3_5_105_1","unstructured":"Aridis Pharmaceuticals Inc. A Phase 1\/2a randomized double-blind two-part dose-ascending multicenter study of the safety and PK of AR-501 (gallium citrate) administered via inhalation in healthy adult and P. aeruginosa infected cystic fibrosis subjects. clinicaltrials.gov; 2023."},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01441-21"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11010041"},{"key":"e_1_3_5_108_1","unstructured":"Peptilogics A Phase 1b open-label dose-escalating study to evaluate the safety and tolerability of PLG0206 in patients undergoing debridement antibiotics and implant retention (DAIR) for treatment of a periprosthetic joint infection (PJI) occurring after total knee arthroplasty (TKA). clinicaltrials.gov; 2025."},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.08.011"},{"key":"e_1_3_5_110_1","unstructured":"Synspira Inc. A multiple-site randomized double-blind placebo-controlled single ascending dose (SAD) study to assess the safety and tolerability of inhaled SNSP113 in healthy male subjects (part a) and subjects with stable cystic fibrosis (part b). clinicaltrials.gov; 2018."},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01721-15"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44731"},{"key":"e_1_3_5_113_1","unstructured":"AlgiPharma AS A double-blind randomized placebo-controlled cross over study of inhaled alginate oligosaccharide (oligoG) administered for 28 days in subjects with cystic fibrosis. clinicaltrials.gov; 2018."},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(14)60182-X"},{"key":"e_1_3_5_115_1","unstructured":"AlgiPharma AS A randomised double-blind placebo-controlled dose-escalation Phase I study to evaluate the safety and tolerability of inhaled aerosolised oligoG CF-5\/20 (g-block oligosaccharide derived from alginate polysaccharide) in healthy volunteers). clinicaltrials.gov; 2016."},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky357"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky357"},{"key":"e_1_3_5_118_1","unstructured":"Alaxia SAS randomized double blind placebo-controlled study of the safety tolerability and pharmacokinetics after single ascending doses or multiple ascending doses of OSCN- BLF or ALX-009 in healthy male and CF and non-CF bronchiectasis patients. clinicaltrials.gov; 2022."},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.17.2400430"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2011.115"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-025-01527-4"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2006.04.015"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-022-01137-4"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00224-06"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59806-y"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14040307"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf203"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.12.026"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1360-5"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1566495"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1571649"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200926050-00001"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02061.x"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2025.2532443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T08:03:21Z","timestamp":1754640201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2025.2532443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":131,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/13543784.2025.2532443"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2025.2532443","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}